XENETIC BIOSCIENCES, INC. Preferred Stock Dividends, Income Statement Impact
XENETIC BIOSCIENCES, INC. (XBIO) reported Preferred Stock Dividends, Income Statement Impact of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2021-03-16
- XENETIC BIOSCIENCES, INC. preferred stock dividends, income statement impact for the quarter ending 2020-12-31 was $0.00.
- XENETIC BIOSCIENCES, INC. preferred stock dividends, income statement impact for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- XENETIC BIOSCIENCES, INC. preferred stock dividends, income statement impact for the quarter ending 2020-06-30 was $0.00.
- XENETIC BIOSCIENCES, INC. preferred stock dividends, income statement impact for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- XENETIC BIOSCIENCES, INC. preferred stock dividends, income statement impact for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- XENETIC BIOSCIENCES, INC. preferred stock dividends, income statement impact for fiscal 2019 was $5.28M.
- XENETIC BIOSCIENCES, INC. preferred stock dividends, income statement impact for fiscal 2018 was $0.00.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $0.00 derived: sum of 2 quarters · filed 2021-03-16 | $0.00 derived: sum of 3 quarters · filed 2021-03-16 | $0.00 10-K · filed 2021-03-16 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-12 | $0.00 derived: sum of 2 quarters · filed 2020-11-12 | $0.00 10-Q · filed 2020-11-12 | $0.00 derived: sum of 4 quarters · filed 2021-03-16 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-12 | $0.00 10-Q · filed 2020-08-12 | $0.00 derived: sum of 3 quarters · filed 2021-03-16 | $1.40M derived: sum of 4 quarters · filed 2021-03-16 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-14 | $0.00 derived: sum of 2 quarters · filed 2021-03-16 | $1.40M derived: sum of 3 quarters · filed 2021-03-16 | $1.40M derived: sum of 4 quarters · filed 2021-03-16 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $1.40M derived: sum of 2 quarters · filed 2021-03-16 | $1.40M derived: sum of 3 quarters · filed 2021-03-16 | $5.28M 10-K · filed 2021-03-16 |
| 2019-09-30 | $1.40M 10-Q · filed 2020-11-12 | $1.40M derived: sum of 2 quarters · filed 2020-11-12 | $5.28M 10-Q · filed 2020-11-12 | $5.28M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-12 | $3.88M 10-Q · filed 2020-08-12 | $3.88M derived: sum of 3 quarters · filed 2020-08-12 | $3.88M derived: sum of 4 quarters · filed 2020-08-12 |
| 2019-03-31 | $3.88M 10-Q · filed 2020-05-14 | $3.88M derived: sum of 2 quarters · filed 2020-05-14 | $3.88M derived: sum of 3 quarters · filed 2020-05-14 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $0.00 derived: sum of 2 quarters · filed 2020-03-26 | $0.00 10-K · filed 2020-03-26 | |
| 2018-09-30 | $0.00 10-Q · filed 2019-11-14 | $0.00 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |